Skip to main content
Premium Trial:

Request an Annual Quote

Amoy Diagnostics, AstraZeneca Partner to Advance PARP Inhibitor CDx For Maintenance Indication

NEW YORK – Chinese diagnostics firm Amoy Diagnostics said Monday that it has entered into a collaboration agreement with AstraZeneca to advance its AmoyDx HRD Complete Panel as a companion diagnostic for the pharma firm's PARP inhibitor Lynparza (olaparib).

Financial terms of the deal were not disclosed.

Olaparib is approved in China for the maintenance treatment of adult patients with HRD-positive advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who have a complete or partial response to first-line chemotherapy in combination with bevacizumab.

Under the agreement, AmoyDx's assay, once approved, would serve as the CDx for the drug in this indication.

AmoyDx announced last year that it was working with AstraZeneca on companion diagnostic projects and disclosed this week that the companies' global collaboration agreement was initially signed in late 2021.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.